Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 2
2005 3
2006 5
2007 4
2008 3
2009 5
2010 6
2011 4
2012 5
2013 8
2014 7
2015 10
2016 13
2017 10
2018 7
2019 12
2020 21
2021 19
2022 34
2023 47
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

207 results

Results by year

Filters applied: . Clear all
Page 1
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).
Silverberg JI, Gooderham MJ, Paller AS, Deleuran M, Bunick CG, Gold LFS, Hijnen D, Calimlim BM, Lee WJ, Teixeira HD, Hu X, Zhang S, Yang Y, Grada A, Platt AM, Thaçi D. Silverberg JI, et al. Among authors: thaci d. Am J Clin Dermatol. 2024 Mar 25. doi: 10.1007/s40257-024-00853-4. Online ahead of print. Am J Clin Dermatol. 2024. PMID: 38528257
Tryptophan degradation as a systems phenomenon in inflammation - an analysis across 13 chronic inflammatory diseases.
Harris DMM, Szymczak S, Schuchardt S, Labrenz J, Tran F, Welz L, Graßhoff H, Zirpel H, Sümbül M, Oumari M, Engelbogen N, Junker R, Conrad C, Thaçi D, Frey N, Franke A, Weidinger S, Hoyer B, Rosenstiel P, Waschina S, Schreiber S, Aden K. Harris DMM, et al. Among authors: thaci d. EBioMedicine. 2024 Apr;102:105056. doi: 10.1016/j.ebiom.2024.105056. Epub 2024 Mar 11. EBioMedicine. 2024. PMID: 38471395 Free PMC article.
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
Strober B, Blauvelt A, Warren RB, Papp KA, Armstrong AW, Gordon KB, Morita A, Alexis AF, Lebwohl M, Foley P, Kisa RM, Colston E, Wang T, Banerjee S, Thaçi D. Strober B, et al. Among authors: thaci d. J Eur Acad Dermatol Venereol. 2024 Mar 7. doi: 10.1111/jdv.19925. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 38451052
Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial.
Koehm M, Rossmanith T, Foldenauer AC, Herrmann E, Brandt-Jürgens J, Burmester GR, Kellner H, Kiltz U, Kofler DM, Rech J, Mojtahed-Poor S, Jonetzko C, Burkhardt H, Behrens F; MUST Investigator Group. Koehm M, et al. Lancet Rheumatol. 2023 Jan;5(1):e14-e23. doi: 10.1016/S2665-9913(22)00329-0. Lancet Rheumatol. 2023. PMID: 38251504 Clinical Trial.
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis.
Blauvelt A, Rich P, Sofen H, Strober B, Merola JF, Lebwohl M, Morita A, Szepietowski JC, Lambert J, Hippeli L, Colston E, Balagula E, Banerjee S, Thaçi D. Blauvelt A, et al. Among authors: thaci d. J Am Acad Dermatol. 2024 Apr;90(4):775-782. doi: 10.1016/j.jaad.2023.11.060. Epub 2023 Dec 18. J Am Acad Dermatol. 2024. PMID: 38122848 Free article. Clinical Trial.
207 results